Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

CAR-Modified Th1/Tc1-Polarized T-Rapa Cells Dissociate Inflammatory Cytokine Secretion from Anti-Tumor Cytotoxicity

Robyn A. A. Oldham, BSc, Tania Felizardo, PhD, Nathaniel Zhu, Daniel H. Fowler, MD, Jeffrey A. Medin, PhD

Blood (2018) 132 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2018-99-113642

Published: 2018

Journal Articles

A Large Cohort Comparison of 2005 National Institutes of Health Chronic Graft-Versus-Host Disease Staging Criteria to 2014 National Institutes of Health Chronic Graft-Versus-Host Disease Staging Criteria

Blood (2017) 130 (Supplement 1): 4720.

https://doi.org/10.1182/blood.V130.Suppl_1.4720.4720

Published: 2017

Journal Articles

PD-1 through Asparaginyl Endopeptidase Regulates Foxp3 Stability in Induced Regulatory T Cells

Grace Mallett, Arun Gangaplara, Chaido Stathopolou, Francis Flomerfelt, Leigh Samsel, Tania Felizardo, Michael Eckhaus, Laura Edgington, Joshua Yim, Jonathan Martinez-Fabregas, Jinfang Zhu, Daniel H. Fowler, MD, Matthew Bogyo, Sanders van-Kasteren, Colin Watts, Ethan Shevach, Arian Dominic John Laurence, PhD MRCP, FRCPath, Shoba Amarnath, BSc, MSc, PhD

Blood (2017) 130 (Supplement 1): 4438.

https://doi.org/10.1182/blood.V130.Suppl_1.4438.4438

Published: 2017

Journal Articles

Final Results of a Randomized Phase 2 Trial Evaluating Lower-Dose Versus Higher-Dose Pomalidomide as Therapy for Corticosteroid-Refractory Chronic Gvhd

Lauren M. Curtis, MD, David Venzon, PhD, Fran T. Hakim, PhD, Edward W. Cowen, MD MHSc, Jennifer Hsu, RN, Licia Masuch, Jacqueline W. Mays, DDS, MHSc, PhD, Sandra A. Mitchell, CRNP, PhD AOCN, Filip Pirsl, Iskra Pusic, MD, Jeremy J. Rose, MS, Zoya J. Kuzmina, MD PhD, Kristin Baird, MD, Robert Peter Gale, Daniel H. Fowler, MD, Ronald E. Gress, MD, Steven Z. Pavletic, MD

Blood (2016) 128 (22): 507.

https://doi.org/10.1182/blood.V128.22.507.507

Published: 2016

Journal Articles

A Randomized Phase 2 Placebo Controlled Trial of Clobetasol Rinse for Treatment of Oral Chronic Graft-Versus-Host Disease

Jacqueline W. Mays, DDS, MHSc, PhD, Lauren M. Curtis, MD, Carol Bassim, DMD, MS, Seth M. Steinberg, PhD, David Venzon, PhD, Jeremy J. Rose, MS, Monica Cho, Christopher G. Kanakry, MD, Fahd Yazdanie, Daniele Avila, NP, Kristin Baird, MD, Jennifer Hsu, RN, Licia Masuch, George Grimes, RPh, Judith Starling, RPh, Daniel H. Fowler, MD, Ronald E. Gress, MD, Fran T. Hakim, PhD, Steven Z. Pavletic, MD

Blood (2016) 128 (22): 826.

https://doi.org/10.1182/blood.V128.22.826.826

Published: 2016

Journal Articles

Clinical and Immunologic Characteristics of Patients with Chronic Graft-Versus-Host Disease Persisting Seven or More Years after Diagnosis

Annie Im, MD, Frances T. Hakim, PhD, Filip Pirsl, Seth M. Steinberg, PhD, Lauren M. Curtis, MD, Sandra A. Mitchell, CRNP, PhD AOCN, Edward W. Cowen, MD MHSc, Jennifer Hsu, RN, Judy Baruffaldi, Licia Masuch, Juan C. Gea-Banacloche, MD, David C. Halverson, MD, Daniel H. Fowler, MD, Ronald E. Gress, MD, Steven Z. Pavletic, MD

Blood (2015) 126 (23): 1937.

https://doi.org/10.1182/blood.V126.23.1937.1937

Published: 2015

Journal Articles

Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial

Blood (2015) 126 (23): 65.

https://doi.org/10.1182/blood.V126.23.65.65

Published: 2015

Journal Articles

Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease

Blood (2015) 126 (23): 99.

https://doi.org/10.1182/blood.V126.23.99.99

Published: 2015

Journal Articles

Upregulation of Interferon-Inducible and Damage Response Receptors in Chronic Graft-Versus-Host Disease

Frances T. Hakim, PhD, Sarfraz Memon, MD, Ping Jin, PhD, Matin M. Imanguli, DDS, MD, Najibah Rehman, MD, Xiao-Yi Yan, MS, Jeremy J. Rose, BA, Jacqueline W. Mays, DDS, PhD, Susan Dhamala, BA, Veena Kapoor, William Telford, PhD, David C. Halverson, MD, Kristin Baird, MD, Daniel H. Fowler, MD, David Stroncek, MD, Edward W. Cowen, MD MHSc, Steven Z. Pavletic, MD, Ronald E. Gress, MD

Blood (2015) 126 (23): 922.

https://doi.org/10.1182/blood.V126.23.922.922

Published: 2015

Journal Articles

Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation

Nancy M. Hardy, MD, Deborah Citrin, MD, Frances T. Hakim, PhD, Daniele N. Avila, CRNP, Bazetta Blacklock-Schuver, RN, Stephanie Cotton, RN, Monica Cho, Daniel H. Fowler, MD, Juan C. Gea-Banacloche, MD, Noa G. Holtzman, MD, Karen A. Kurdziel, MD, Sarfraz Memon, MD, Steven Z. Pavletic, MD, Stefania Pittaluga, MD PhD, Jeremy J. Rose, BA, Claude Sportes, MD, Jennifer S. Wilder, RN, Ronald E. Gress, MD, Michael R. Bishop, MD

Blood (2015) 126 (23): 1962.

https://doi.org/10.1182/blood.V126.23.1962.1962

Published: 2015

Journal Articles

Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia

Blood (2014) 124 (21): 679.

https://doi.org/10.1182/blood.V124.21.679.679

Published: 2014

Journal Articles

FLT Imaging Reveals Kinetics and Biology of Engraftment after Myeloablative HSCT

Blood (2014) 124 (21): 1147.

https://doi.org/10.1182/blood.V124.21.1147.1147

Published: 2014

Journal Articles

Comparable 3-Year Disease-Free Survival Regardless of Anti-Thymocyte Globulin Inclusion in Pediatric Myeloablative Cord Blood Transplantation for Acute Lymphoblastic Leukemia

Doris M. Ponce, MD, Rodney Sparapani, PhD, Junfang Chen, MS, Vanderson Rocha, MD PhD, Daniel H. Fowler, MD, Mary Eapen, MBBS, Juliet N. Barker, MBBS(Hons), FRACP, Miguel-Angel Perales, MD

Blood (2014) 124 (21): 1259.

https://doi.org/10.1182/blood.V124.21.1259.1259

Published: 2014

Journal Articles

Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2013) 122 (21): 151.

https://doi.org/10.1182/blood.V122.21.151.151

Published: 2013

Journal Articles

Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.

Rachel B. Salit, MD, Frances T. Hakim, PhD, Michael R. Bishop, MD, Thea M. Friedman, PhD, Robert Korngold, PhD, Kira Goldgirsh, PhD, Sarfraz Memon, MD, Seth M. Steinberg, PhD, David Liewehr, MS, Daniel Peaceman, BS, Jennifer Wilder, RN, Kelly Bryant, RN, Daniel H. Fowler, MD, Juan Gea-Banacloche, MD, Ronald E. Gress, MD, Steven Z. Pavletic, MD

Blood (2012) 120 (21): 3054.

https://doi.org/10.1182/blood.V120.21.3054.3054

Published: 2012

Journal Articles

Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT

Blood (2012) 120 (21): 471.

https://doi.org/10.1182/blood.V120.21.471.471

Published: 2012

Journal Articles

Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism

Rachel B. Salit, MD, Michael R. Bishop, MD, Steven Z. Pavletic, MD, Frances T. Hakim, PhD, Seth M. Steinberg, PhD, Jeanne Odom, RN, Kelly Bryant, RN, Jennifer Wilder, RN, Daniele N. Avila, CRNP, Bazetta Blacklock-Schuver, RN, Ronald E. Gress, MD, Daniel H. Fowler, MD

Blood (2011) 118 (21): 1937.

https://doi.org/10.1182/blood.V118.21.1937.1937

Published: 2011

Journal Articles

Costimulated, Tumor-Derived Donor Lymphocyte (TDL) Infusion for B-Cell Tumor Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Nancy M. Hardy, MD, Vicki Fellowes, Jeremy Rose, PhD, Daniel H. Fowler, MD, Ronald E. Gress, MD, Bruce L. Levine, PhD, Carl H. June, MD, Frances T Hakim, PhD, Michael R. Bishop, MD

Blood (2010) 116 (21): 683.

https://doi.org/10.1182/blood.V116.21.683.683

Published: 2010

Journal Articles

Use of Targeted Lymphocyte Depletion as a Personalized Approach to Improve Engraftment and Disease Control Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors

Rachel B. Salit, MD, Steven Z. Pavletic, MD, Daniel H. Fowler, MD, Jennifer Wilder, RN, Kelly Bryant, RN, Seth M. Steinberg, PhD, Frances T. Hakim, PhD, Michael R. Bishop, MD

Blood (2010) 116 (21): 3530.

https://doi.org/10.1182/blood.V116.21.3530.3530

Published: 2010

Journal Articles

Incidence, Risks, and Outcomes of Relapse Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma.

Michael R. Bishop, MD, Seth Steinberg, PhD, Nancy M. Hardy, MD, Steven Z. Pavletic, MD, Ronald E. Gress, MD, Rachel B. Salit, MD, Paula Layton, BSN, Daniel H. Fowler, MD

Blood (2010) 116 (21): 3451.

https://doi.org/10.1182/blood.V116.21.3451.3451

Published: 2010

NARROW

CAR-Modified Th1/Tc1-Polarized T-Rapa Cells Dissociate Inflammatory Cytokine Secretion from Anti-Tumor Cytotoxicity

A Large Cohort Comparison of 2005 National Institutes of Health Chronic Graft-Versus-Host Disease Staging Criteria to 2014 National Institutes of Health Chronic Graft-Versus-Host Disease Staging Criteria

PD-1 through Asparaginyl Endopeptidase Regulates Foxp3 Stability in Induced Regulatory T Cells

Final Results of a Randomized Phase 2 Trial Evaluating Lower-Dose Versus Higher-Dose Pomalidomide as Therapy for Corticosteroid-Refractory Chronic Gvhd

A Randomized Phase 2 Placebo Controlled Trial of Clobetasol Rinse for Treatment of Oral Chronic Graft-Versus-Host Disease

Clinical and Immunologic Characteristics of Patients with Chronic Graft-Versus-Host Disease Persisting Seven or More Years after Diagnosis

Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial

Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease

Upregulation of Interferon-Inducible and Damage Response Receptors in Chronic Graft-Versus-Host Disease

Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation

Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia

FLT Imaging Reveals Kinetics and Biology of Engraftment after Myeloablative HSCT

Comparable 3-Year Disease-Free Survival Regardless of Anti-Thymocyte Globulin Inclusion in Pediatric Myeloablative Cord Blood Transplantation for Acute Lymphoblastic Leukemia

Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation

Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.

Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT

Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism

Costimulated, Tumor-Derived Donor Lymphocyte (TDL) Infusion for B-Cell Tumor Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Use of Targeted Lymphocyte Depletion as a Personalized Approach to Improve Engraftment and Disease Control Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors

Incidence, Risks, and Outcomes of Relapse Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only